<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

New formulations of existing active substances are...

The Opinion of Advocate General Saugmandsgaard Øe in Abraxis Bioscience (Ca...

Read More

Transforming health and social care: industry pers...

At a roundtable event in London in September 2018, CMS assembled a selectio...

Read More

Vital signs in UK life sciences

In 2017, Professor Sir John Bell published the well-received Life Sciences ...

Read More

A Right Pain in the Peripheries? The Supreme Court...

Summary

Read More

AI update: medical software and pre-emption

In light of the rapidly expanding field of medical software technology, and...

Read More

Artificial intelligence and machine learning in he...

Artificial intelligence (AI), particularly machine learning (ML), is alread...

Read More

Addressing emerging themes in life science IP

Marks & Clerk’s intellectual property (IP) summit in Cambridge on 16 Octobe...

Read More

M&A deals and the pharmaceutical sector: Are your ...

2018 has so far been a productive year for M&A deals in the pharmaceutical ...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

C-Suite challenges and how intellectual property c...

The 2018 C-Suite Challenges in Life Sciences Survey from Biotech & Money/LS...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More

In a new age of personalised cancer therapy, is pa...

On 5 September 2018 it was announced that the NHS has struck a deal with No...

Read More

Add Your Response